// App-Quantinova.ai

143 : The PARASAIL study- Patient Reported Outcomes from the Canadian Real World Experience use of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction

Researchers

Presenter

  • Haissam Haddad

Principal Investigators

  • Sebastien Bergeron

  • Andrew Ignaszewski

  • Gregory Searles

  • Driss Rochdi

  • Natacha Bastien

Medical Centers

  • University of Saskatchewan, Saskatoon, SK, Canada

  • Centre de Recherche de lInstitut Universitaire de Cardiologie et de Pneumologie de Quebec/INAF, Quebec, Quebec, Canada

  • The University of British Columbia, Vancouver, BC, Canada

  • Saint John Regional Hospital, Saint John, NB, Canada

  • Novartis Pharmaceuticals Canada Inc Dorval QC Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • Sex hormone binding globulin

Drug/Treatment

  • Sacubitril/valsartan

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved